Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.75 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.75 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.62 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3372659 | 1.00 | CTSB (0.75) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL3369276 | 0.96 | CTSB (0.81) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL13757649 | 0.96 | CTSB (0.81) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL10271478 | 0.94 | CTSB (0.66) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL14864648 | 0.92 | CTSB (0.74) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL14731707 | 0.92 | CTSB (0.74) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL10220951 | 0.92 | CTSB (0.74) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL10220270 | 0.92 | CTSB (0.74) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL10220364 | 0.92 | CTSB (0.74) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL10271498 | 0.92 | CTSB (0.74) | CTSBPPP3CBABCC1ABCC2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | CTSB 630/4885PPP3CB 1553/4885ABCC1 1980/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CTSB 630/4885PPP3CB 1553/4885ABCC1 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.